Clinical outcomes with alternative dosing strategies for piperacillin/tazobactam: a systematic review and meta-analysis.

Clinical outcomes with alternative dosing strategies for piperacillin/tazobactam: a systematic review and meta-analysis.

OBJECTIVES:A better dosing strategy can improve clinical outcomes for patients. We sought to compare the extended or continuous infusion with conventional intermittent infusion of piperacillin/tazobactam, investigating which approach is better and worthy of recommendation for clinical use. METHODS:A...

Full description

Bibliographic Details
Main Authors:	Hui Yang, Chao Zhang, Quanyu Zhou, Yike Wang, Lujia Chen
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2015-01-01
Series:	PLoS ONE
Online Access:	http://europepmc.org/articles/PMC4289069?pdf=render

Similar Items

Evaluation Outcomes Associated with Alternative Dosing Strategies for Piperacillin/Tazobactam: A Systematic Review and Meta-Analysis
by: Hui Yang, et al.
Published: (2016-08-01)

Piperacillin–tazobactam as alternative to carbapenems for ICU patients
by: Benoit Pilmis, et al.
Published: (2017-11-01)

Piperacillin/Tazobactam (ZOSYN)
by: Stephanie M. Culver, et al.
Published: (1996-01-01)

Comparing clinical outcomes of piperacillin-tazobactam administration and dosage strategies in critically ill adult patients: a systematic review and meta-analysis
by: Sarah Fawaz, et al.
Published: (2020-06-01)

Piperacillin/Tazobactam as Cause of Acute Generalized Exanthematous Pustulosis
by: Aikaterini Kyriakou, et al.
Published: (2019-01-01)

Piperacillin/Tazobactam-Induced Neutropenia: A Case Report
by: Hayati DEMİRASLAN, et al.
Published: (2012-03-01)

Piperacilina/tazobactam en el sistema VITEK ®2 Piperacillin / Tazobactam in the VITEk ®2 System
by: Javier Gutman, et al.
Published: (2011-06-01)

The potential of meropenem and piperacillin-tazobactam combination to Acinetobacter spp clinical isolates in vitro
by: Alindya Diani, et al.
Published: (2020-02-01)

A meta-analysis of piperacillin/tazobactam versus cefepime treatment in cancer patients with febrile neutropenia
by: Zhang Weidong, et al.
Published: (2016-12-01)

Results of the effectiveness of two piperacillin–tazobactam molecules in the real world
by: Jorge Enrique Machado-Alba, et al.
Published: (2018-11-01)

<i>Enterobacter </i>endophthalmitis: Treatment with intravitreal tazobactam- piperacillin
by: Singh Trehan, et al.
Published: (2007-01-01)

Penetration of Piperacillin/Tazobactam Into Gynecologic Tissues Following a Single Loading Dose Prior to Hysterectomy
by: William F. O'Brien, et al.
Published: (1994-01-01)

Ertapenem versus piperacillin/tazobactam for the treatment of complicated infections: a meta-analysis of randomized controlled trials
by: Liu Ping, et al.
Published: (2009-12-01)

Incidence and impact on clinical outcome of infections with piperacillin/tazobactam resistant <it>Escherichia coli </it>in ICU: A retrospective study
by: Mounier Roman, et al.
Published: (2008-05-01)

Galactomannan detection from piperacillin-tazobactam brands available in the Brazilian market
by: Melissa Orzechowski Xavier, et al.

In Vitro Synergy of Levofloxacin Plus Piperacillin/Tazobactam against Pseudomonas aeruginosa
by: Vladimir Chachanidze, et al.
Published: (2009-01-01)

Impact on Bacterial Resistance of Therapeutically Nonequivalent Generics: The Case of Piperacillin-Tazobactam.
by: Carlos A Rodriguez, et al.
Published: (2016-01-01)

Evaluation of Implementation of Extended-Infusion Piperacillin-Tazobactam at an Academic Medical Center
by: Radosevich, John, et al.
Published: (2011)

Risk factors of nosocomial infections caused by piperacillin-tazobactam resistant Pseudomonas aeruginosa
by: Đorđević Zorana, et al.
Published: (2013-01-01)

Impact of piperacillin-tazobactam shortage on meropenem use: implications for antimicrobial stewardship programs
by: Katie E. Barber, et al.
Published: (2016-11-01)

A Case of DRESS Syndrome Associated with Piperacillin-Tazobactam Treatment and Literature Review
by: Seven ULUDOKUMACI, et al.
Published: (2012-12-01)

Synthesis and evaluation of polymeric micelle containing piperacillin/tazobactam for enhanced antibacterial activity
by: Milani Morteza, et al.
Published: (2019-01-01)

Extensive Gene Amplification as a Mechanism for Piperacillin-Tazobactam Resistance in Escherichia coli
by: Lisa M. Schechter, et al.
Published: (2018-04-01)

Acute kidney injury associated with concomitant use of vancomycin with piperacillin-tazobactam: a focused review and meta-analysis
by: Hatice Duygu Bas, et al.
Published: (2016-06-01)

Increased dosing regimens of piperacillin-tazobactam are needed to avoid subtherapeutic exposure in critically ill patients with augmented renal clearance
by: Thibaud Besnard, et al.
Published: (2019-01-01)

Population Pharmacokinetic Modeling and Pharmacodynamic Target Attainment Simulation of Piperacillin/Tazobactam for Dosing Optimization in Late Elderly Patients with Pneumonia
by: Noriyuki Ishihara, et al.
Published: (2020-03-01)

Comparison of piperacillin plasma concentrations in a prospective randomised trial of extended infusion versus intermittent bolus of piperacillin/tazobactam in paediatric patients
by: Tatchanapong Chongcharoenyanon, et al.
Published: (2021-07-01)

Characterization of Piperacillin/Tazobactam-Resistant Klebsiella oxytoca Recovered from a Nosocomial Outbreak.
by: Ai Fujita, et al.
Published: (2015-01-01)

Acute Kidney Injury in Pediatric Treated with Vancomycin and Piperacillin-Tazobactam in Tertiary Care Hospital
by: Mohammed Al Nuhait, et al.
Published: (2018-01-01)

Development of Clostridium difficile resistance to Piperacillin/Tazobactam over a period of ten years
by: Ahlund, Veronica
Published: (2017)

Outpatient therapy with piperacillin/tazobactam using elastomeric pumps in patients with Pseudomonas aeruginosa infection
by: Jose Luis Lamas Ferreiro, et al.
Published: (2021-04-01)

Pharmacokinetics and outcome of tazobactam/piperacillin in Japanese patients undergoing low-flow continuous renal replacement therapy: dosage considerations
by: Kohama H, et al.
Published: (2017-02-01)

Integrated Genome-Wide Analysis of an Isogenic Pair of <i>Pseudomonas aeruginosa</i> Clinical Isolates with Differential Antimicrobial Resistance to Ceftolozane/Tazobactam, Ceftazidime/Avibactam, and Piperacillin/Tazobactam
by: Weihua Huang, et al.
Published: (2020-02-01)

Efflux Pump AcrAB Confers Decreased Susceptibility to Piperacillin–Tazobactam and Ceftolozane–Tazobactam in Tigecycline-Non-Susceptible Klebsiella pneumoniae
by: Li J, et al.
Published: (2020-11-01)

An Investigation of Aspects Affecting Availability and the Health-economical Consequences of Shortages ofVancomycin and Piperacillin/Tazobactam
by: Cederwall, Ida, et al.
Published: (2020)

Evaluating the appropriateness of carbapenem and piperacillin-tazobactam prescribing in a tertiary care hospital in Saudi Arabia
by: Nada A Alsaleh, et al.
Published: (2020-11-01)

Prospective evaluating the appropriate use of piperacillin /tazobactam in cardiac center of a tertiary care hospital
by: Sanaa Saeed Mekdad, et al.
Published: (2020-05-01)

Comparison of the incidence of acute kidney injury during treatment with vancomycin in combination with piperacillin–tazobactam or with meropenem
by: Majed S. Al Yami
Published: (2017-11-01)

Study of the Comparative Activity of Piperacillin/Tazobactam with Currently Available Antibiotics against 8206 Aerobic Isolates
by: Kevin R Forward, et al.
Published: (1997-01-01)

Randomized Comparison of Piperacillin/Tazobactam Versus Imipenem/Cilastatin in the Treatment of Patients with Intra-abdominal Infection
by: Alex A. Erasmo
Published: (2004-07-01)